SG11202109025XA - Combinations of iadademstat for cancer therapy - Google Patents

Combinations of iadademstat for cancer therapy

Info

Publication number
SG11202109025XA
SG11202109025XA SG11202109025XA SG11202109025XA SG11202109025XA SG 11202109025X A SG11202109025X A SG 11202109025XA SG 11202109025X A SG11202109025X A SG 11202109025XA SG 11202109025X A SG11202109025X A SG 11202109025XA SG 11202109025X A SG11202109025X A SG 11202109025XA
Authority
SG
Singapore
Prior art keywords
iadademstat
combinations
cancer therapy
cancer
therapy
Prior art date
Application number
SG11202109025XA
Other languages
English (en)
Inventor
Filippo Ciceri
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of SG11202109025XA publication Critical patent/SG11202109025XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202109025XA 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy SG11202109025XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Publications (1)

Publication Number Publication Date
SG11202109025XA true SG11202109025XA (en) 2021-09-29

Family

ID=66175363

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109025XA SG11202109025XA (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC7.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210142614A (cg-RX-API-DMAC7.html)
CN (2) CN113573702A (cg-RX-API-DMAC7.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC7.html)
IL (1) IL286353A (cg-RX-API-DMAC7.html)
MX (1) MX2021011610A (cg-RX-API-DMAC7.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC7.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US20190256929A1 (en) * 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Also Published As

Publication number Publication date
CN113573702A (zh) 2021-10-29
JP7824627B2 (ja) 2026-03-05
JP2026077769A (ja) 2026-05-13
KR20210142614A (ko) 2021-11-25
AU2020249493A1 (en) 2021-09-16
PH12021552326A1 (en) 2022-06-27
JP2022526525A (ja) 2022-05-25
EP3946295A1 (en) 2022-02-09
BR112021016171A2 (pt) 2021-10-05
CA3132473A1 (en) 2020-10-01
CN121422229A (zh) 2026-01-30
US20220175698A1 (en) 2022-06-09
WO2020193631A1 (en) 2020-10-01
EP3946295B1 (en) 2026-08-05
AU2020249493B2 (en) 2025-08-28
IL286353A (en) 2021-10-31
MX2021011610A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
EP4010081A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
ZA202206743B (en) Therapy for the treatment of cancer
IL267795A (en) Combined treatment for cancer
ZA202005847B (en) Cancer therapy
GB201903546D0 (en) Cancer treatment
IL282093B1 (en) Combination therapy for cancer
SG11202011117VA (en) Treatment of cancer
IL285807A (en) Immunotherapy for cancer treatment
GB201905780D0 (en) Cancer therapy
SG11202103141YA (en) Combination therapy for the treatment of cancer
EP3897649A4 (en) COMBINATION THERAPY FOR SOLID TUMOR
IL266993A (en) Combined therapy for cancer treatment
SG11202107017TA (en) Methods of treating cancer
IL289201A (en) Compounds for the treatment of cancer
SG11202107850VA (en) Cancer treatment
IL284162A (en) Integrated healing for cancer treatment
IL279591A (en) Cancer treatment methods using combination therapy
GB201820098D0 (en) Methods of cancer treatment
GB202301902D0 (en) Combination therapy for cancer
GB201918815D0 (en) Treatment of cancer
GB201820975D0 (en) Methods of cancer treatment
HK40069796A (en) Combinations of iadademstat for cancer therapy
IL253642A0 (en) Combined treatment for cancer
GB201901368D0 (en) Cancer therapy